fbpx Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science.

Pfizer and BioNTech Settle on COVID-19 Vaccine Deal with U.S. Government, Encoded Therapeutics Receives Funding to Advance Gene Therapy, Gilead Ponies Up for Tizona

  • 2020-07-22T19:00:00.000+0000
  • California
  • Author: Lauren Panetta

7/22/20 – BioSpace

Pfizer and BioNTech Ink $1.95 Billion COVID-19 Vaccine Deal with U.S. Government

7/22/20 – Ultragenyx

Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

7/22/20 – FierceBiotech

Encoded Therapeutics bags $135M to push 'precision gene therapy' into the clinic

7/22/20 – BioSpace

Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures

7/22/20 – Seer

Seer Announces $55M Financing Led by Fidelity Management and Research Company

7/22/20 – FierceBiotech

Planning ahead: U.S., Canada order 177M more COVID-19 vaccine syringes from BD

7/22/20 – BioSpace

NuVasive's Less Invasive Procedural Solutions Are Clinically Proven to Reduce Operative Time and Improve Patient Outcomes in Spine Surgery

7/22/20 – Regulus Therapeutics

Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

7/21/20 – Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys receives CIRM award for COVID-19 research

7/21/20 – CalciMedica

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

7/21/20 – Fulcrum Therapeutics

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

7/21/20 – Xconomy

Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire

7/20/20 – The San Diego Union-Tribune

Sorrento Therapeutics to test anti-inflammatory drug in COVID-19 trial

7/20/20 – ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

7/20/20 – Endpoints News

Amplyx touts upbeat readout from a small PhII study for lead antifungal

7/17/20 – FierceBiotech

Roche, Genentech turn to PicnicHealth to tap multiple sclerosis patient data

7/16/20 – PhaseBio

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

7/16/20 – Twist Bioscience

Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

7/16/20 – FierceBiotech

Thermo Fisher throws in an extra $1B for its Qiagen takeover bid

7/16/20 – Kronos Bio

Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead's SYK Inhibitor Portfolio

7/15/20 – BioAtla

BioAtla Raises $72.5 Million In Series D Financing

7/15/20 – BridgeBio Pharma

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

7/13/20 – Xconomy

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More